BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Reuters12-08 20:51
BUZZ-<a href="https://laohu8.com/S/RXRX">Recursion</a> climbs as experimental drug reduces polyp growth in rare disease trial

** Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket

** Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis

** In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy

** Co is looking to expand the study to a broader population of patients aged 18 years and above

** Up to last close, stock down 30.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment